MedTrace Logo

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

NCT01316692 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-05-30

Study results available
· View outcomes & findings →

Summary

RATIONALE: Aurora A kinase inhibitor MLN8237 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well Aurora A kinase inhibitor MLN8237 works in treating patients with unresectable stage III-IV melanoma

Funding Source - FDA OOPD

Conditions

  • Recurrent Melanoma
  • Stage IIIc Melanoma
  • Stage IV Melanoma

Interventions

OTHER

laboratory biomarker identification and analysis

Correlative studies

PROCEDURE

biopsy

Correlative studies

OTHER

immunohistochemistry/tissue microarrays

Correlative studies

GENETIC

TdT-mediated dUTP nick end labeling assay

Correlative studies

OTHER

mass spectrometry

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Jeffrey Sosman, MD · Vanderbilt-Ingram Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-11-30
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01316692 on ClinicalTrials.gov